US 12,215,118 B2
Quinone methide analog signal amplification
Christopher Bieniarz, Tucson, AZ (US); Julia Ashworth-Sharpe, Tucson, AZ (US); Brian D. Kelly, Tucson, AZ (US); and Nathan Polaske, Oracle, AZ (US)
Assigned to Ventana Medical Systems, Inc., Tucson, AZ (US)
Filed by Ventana Medical Systems, Inc., Tucson, AZ (US)
Filed on Oct. 22, 2021, as Appl. No. 17/507,853.
Application 17/507,853 is a division of application No. 16/183,570, filed on Nov. 7, 2018, granted, now 11,365,210.
Application 16/183,570 is a continuation of application No. 15/246,430, filed on Aug. 24, 2016, granted, now 10,168,336, issued on Jan. 1, 2019.
Application 15/246,430 is a continuation of application No. PCT/EP2015/053556, filed on Feb. 20, 2015.
Claims priority of provisional application 61/943,940, filed on Feb. 24, 2014.
Prior Publication US 2022/0041633 A1, Feb. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/58 (2006.01); C07D 209/14 (2006.01); C07D 403/06 (2006.01); C07F 9/06 (2006.01); C07F 9/12 (2006.01); C07F 9/58 (2006.01); C07F 9/6503 (2006.01); C07F 9/6518 (2006.01); C07F 9/6533 (2006.01); C07F 9/6558 (2006.01); C07F 9/6561 (2006.01); C07H 15/203 (2006.01); C07H 15/207 (2006.01); C07H 15/26 (2006.01); C07H 17/02 (2006.01); C12Q 1/42 (2006.01)
CPC C07F 9/6561 (2013.01) [C07D 209/14 (2013.01); C07D 403/06 (2013.01); C07F 9/06 (2013.01); C07F 9/12 (2013.01); C07F 9/58 (2013.01); C07F 9/65031 (2013.01); C07F 9/6518 (2013.01); C07F 9/65335 (2013.01); C07F 9/65583 (2013.01); C07H 15/203 (2013.01); C07H 15/207 (2013.01); C07H 15/26 (2013.01); C07H 17/02 (2013.01); C12Q 1/42 (2013.01); G01N 33/581 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A method of detecting a first target in a biological sample, comprising:
contacting the biological sample with a first detection probe specific to the first target;
labeling the first target with a first enzyme through the first detection probe;
contacting the biological sample with a first quinone methide analog precursor comprising a first enzyme recognition group and a first detectable label, and
detecting the first target by detecting the first detectable label,
wherein the first quinone methide analog precursor has a formula

OG Complex Work Unit Chemistry
or a salt or solvate thereof;
Z is O, S or NRa and R1 is an enzyme recognition group, or ZR1 is an enzyme recognition group;
R8 is —C(LG)(R5)(R3R4);
R9, R11 and R12 are each independently hydrogen, halo, cyano, aliphatic, alkoxy, NO2, N(Rc)2, aryl, —C(O)alkyl, —C(S)alkyl, —C(O)OH, —C(O)Oalkyl, —C(O)NHRc, —C(O)N(Rc)2, —R3R4 or two adjacent groups together form an aliphatic ring or aryl ring;
R10 is hydrogen, halo, cyano, aliphatic, alkoxy, NO2, N(Rc)2, aryl, haloalkyl, —C(O)alkyl, —C(S)alkyl, —C(O)OH, —C(O)Oalkyl, —C(O)NHRc, —C(O)N(Rc)2, or with one of R9 or R11 form an aliphatic ring or aryl ring;
LG is a leaving group, or ZR1 and LG together form a phosphodiester;
R3 is —N(H)C(O)(CH2)nNH—,—C(O)N(H)(CH2)nNH—,
—C(O)N(H)(CH2)nO—, —N(H)C(O)(CH2)nS—, —C(O)N(H)(CH2)nS—,
—C(O)N(H)(CH2)nNHC(O)CH(CH3)(CH2)nNH—, or —N(H)(CH2)nNH—, where each n is independently an integer ranging from 1 to 12;
R4 is a chromogen, a fluorophore, a luminophore, or a hapten, wherein the hapten is selected from the group consisting of a pyrazole, a nitrophenyl compound, a benzofuran, a urea, a thiourea, a phenyl urea, a phenyl thiourea, a rotenone, a rotenone derivative, an oxazole, a thiazole, a coumarin, a coumarin derivative, or a cyclolignan;
each Ra independently is hydrogen or aliphatic;
each Rc independently is hydrogen, aryl, aliphatic or heteroaliphatic, or two Rc moieties together form a heteroaliphatic ring;
each R5 is independently hydrogen, halo, cyano, lower alkyl, lower haloalkyl, —C(O)alkyl, —C(S)alkyl, —C(O)OH, —C(O)Oalkyl, —C(O)NHRc or —C(O)N(Rc)2;
and
if LG is halo, then R5 is not halo.